• MJHLS Brand Logo

© 2020 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.

Peer Exchange

Supporting Cross-Benefit Management of Infused Drugs

Choosing Drug-related Routes of Administration
Choosing Drug-related Routes of Administration
Routes of Administration: Adherence and Persistence
Routes of Administration: Adherence and Persistence
Alignment of Incentives: Optimizing Routes of Administration
Alignment of Incentives: Optimizing Routes of Administration
Cost Considerations for Self- vs HCP-administered Agents
Cost Considerations for Self- vs HCP-administered Agents
Preferred Site of Care and Coverage for Infusions
Preferred Site of Care and Coverage for Infusions
Utilization Management Through Medical and Pharmacy Benefit
Utilization Management Through Medical and Pharmacy Benefit
Cost Dispersion of Infused Drugs
Cost Dispersion of Infused Drugs
Self-injectables: Emerging Agents for the Management of MS
Self-injectables: Emerging Agents for the Management of MS
Evolving Management of Drug Spending Monitoring
Evolving Management of Drug Spending Monitoring
Transparency Among Medical and Pharmacy Benefits
Transparency Among Medical and Pharmacy Benefits
Management of Drug Spending and Impact of COVID-19
Management of Drug Spending and Impact of COVID-19
Future of Medical and Pharmacy Benefit Integration
Future of Medical and Pharmacy Benefit Integration

Considering Cost Effectiveness in Cardiovascular Risk Reduction

Economic Burden of Cardiovascular Disease
Economic Burden of Cardiovascular Disease
Risk Assessment for Cardiovascular Disease
Risk Assessment for Cardiovascular Disease
LDL Cholesterol Lowering and CV Risk
LDL Cholesterol Lowering and CV Risk
Cardiovascular Risk Management
Cardiovascular Risk Management
Dyslipidemia: Strategies Used to Reduce CV Risk
Dyslipidemia: Strategies Used to Reduce CV Risk
Statin Therapy for LDL Reduction and CV Risk
Statin Therapy for LDL Reduction and CV Risk
Statin Therapy: Risk for Future CV Events
Statin Therapy: Risk for Future CV Events
PCSK9 Inhibitors and CV Risk
PCSK9 Inhibitors and CV Risk
Dyslipidemia: Cost-Utilization of PCSK9 Inhibitors
Dyslipidemia: Cost-Utilization of PCSK9 Inhibitors
Targeting Triglycerides to Reduce CV Risk
Targeting Triglycerides to Reduce CV Risk
The REDUCE-IT Study and CV Risk
The REDUCE-IT Study and CV Risk
Interim Analysis of EVAPORATE
Interim Analysis of EVAPORATE
Coronary Plaque Regression and CV Risk
Coronary Plaque Regression and CV Risk
Implications for Treating Patients With Icosapent Ethyl
Implications for Treating Patients With Icosapent Ethyl
Cost-Effectiveness and Cardiovascular Risk
Cost-Effectiveness and Cardiovascular Risk
Cardiovascular Disease Treatment Decisions and Cost
Cardiovascular Disease Treatment Decisions and Cost
CV Risk Reduction and Coverage of Therapies
CV Risk Reduction and Coverage of Therapies
Cost-Effectiveness Data and Pricing of Icosapent Ethyl
Cost-Effectiveness Data and Pricing of Icosapent Ethyl
CVD: Cost-Effectiveness Data and Treatment Selection
CVD: Cost-Effectiveness Data and Treatment Selection
Clinical Pathways for Cardiovascular Disease Management
Clinical Pathways for Cardiovascular Disease Management
Better Strategies to Reduce Cardiovascular Events
Better Strategies to Reduce Cardiovascular Events

Quantifying the Potential Impact of SGLT-2 Inhibitors in Heart Failure

Pathophysiology of Different Types of Heart Failure
Pathophysiology of Different Types of Heart Failure
Progressive Nature and Associated Risks of Diabetes on HF
Progressive Nature and Associated Risks of Diabetes on HF
Cost and Utilization Profile for a Patient With HF
Cost and Utilization Profile for a Patient With HF
Economic Burden of Heart Failure and Goals of Treatment
Economic Burden of Heart Failure and Goals of Treatment
Standard of Care in Patients With Heart Failure
Standard of Care in Patients With Heart Failure
Reducing Readmissions Due to Heart Failure
Reducing Readmissions Due to Heart Failure
CV Outcomes Studies With Medications Indicated for Diabetes
CV Outcomes Studies With Medications Indicated for Diabetes
Recent Studies of SGLT-2s in Patients with HFrEF
Recent Studies of SGLT-2s in Patients with HFrEF
Implications of Using SGLT2 Inhibitors With HFpEF and HFrEF
Implications of Using SGLT2 Inhibitors With HFpEF and HFrEF
SGLT2 Inhibitors in Patients Without Diabetes at Risk of HF
SGLT2 Inhibitors in Patients Without Diabetes at Risk of HF
SGLT2 Inhibitors as Standard of Care Throughout Cardiology
SGLT2 Inhibitors as Standard of Care Throughout Cardiology
Guidelines Regarding Use of SGLT2s for Patients With Diabetes and HF
Guidelines Regarding Use of SGLT2s for Patients With Diabetes and HF
Quantifying Potential Impact of SGLT2 Inhibitors for HF
Quantifying Potential Impact of SGLT2 Inhibitors for HF
Systemic Change to Support Care of Patients With HF
Systemic Change to Support Care of Patients With HF
Treatment of Patients With Heart Failure
Treatment of Patients With Heart Failure
Interest Regarding Diabetes and CVD Risk
Interest Regarding Diabetes and CVD Risk
Takeaways of DAPA-HF: SGLT2s for CVD
Takeaways of DAPA-HF: SGLT2s for CVD
Using SGLT2 Inhibitors to Achieve Cardiovascular Benefits
Using SGLT2 Inhibitors to Achieve Cardiovascular Benefits
Cost-Effectiveness of SGLT2s for CVD
Cost-Effectiveness of SGLT2s for CVD

Value-based Considerations of CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer

Patient Journey and Development of Metastatic Breast Cancer
Patient Journey and Development of Metastatic Breast Cancer
Patient, Advocate, and Payer on Value-Based Care for mBC
Patient, Advocate, and Payer on Value-Based Care for mBC
Provider Perspective on Value-Based Care for mBC
Provider Perspective on Value-Based Care for mBC
Patient Cost Burden for Metastatic Breast Cancer Therapy
Patient Cost Burden for Metastatic Breast Cancer Therapy
Provider Responsibility to Cost Burden for mBC Therapy
Provider Responsibility to Cost Burden for mBC Therapy
Value-Based Care vs Cost of Treatment for mBC
Value-Based Care vs Cost of Treatment for mBC
First-line Therapy for HR-Positive, HER2-Negative mBC
First-line Therapy for HR-Positive, HER2-Negative mBC
Pivotal Studies for CDK4/6 Inhibitors
Pivotal Studies for CDK4/6 Inhibitors
Role of CDK4/6 Inhibitors and Patient Selection
Role of CDK4/6 Inhibitors and Patient Selection
Distinguishing Among the Available CDK4/6 Inhibitors
Distinguishing Among the Available CDK4/6 Inhibitors
Formulary Consideration and Clinical Impact of Cost
Formulary Consideration and Clinical Impact of Cost
Breast Cancer Management: Global Cost of Care
Breast Cancer Management: Global Cost of Care
Defining Episode of Care in Metastatic Disease
Defining Episode of Care in Metastatic Disease
Breast Cancer Pathway Guidelines for Practitioners
Breast Cancer Pathway Guidelines for Practitioners
Payer Approval for Frontline Options: Restrictive or Broad?
Payer Approval for Frontline Options: Restrictive or Broad?
The Impact of Patient Preference on Payer Compliance
The Impact of Patient Preference on Payer Compliance
Breast Cancer Treatment: How COVID-19 Has Altered Care
Breast Cancer Treatment: How COVID-19 Has Altered Care
Adjuvant CDK4/6 Inhibition: When it Will Become Routine
Adjuvant CDK4/6 Inhibition: When it Will Become Routine
Development of Clinical Pathways and Patient Characteristics
Development of Clinical Pathways and Patient Characteristics
Adding Multiple in a Class and Measuring Success of Pathways
Adding Multiple in a Class and Measuring Success of Pathways
Outcomes and Future of Clinical Pathways
Outcomes and Future of Clinical Pathways

Managed Care Consideration for an Emerging Class of Therapy in Anemia of Chronic Kidney Disease

Overview of Chronic Kidney Disease
Overview of Chronic Kidney Disease
Role of Anemia in CKD
Role of Anemia in CKD
Payer Perspective of Anemia in CKD
Payer Perspective of Anemia in CKD
Treatment of Anemia in CKD
Treatment of Anemia in CKD
Standard of Care: Therapeutic Options for Anemia in CKD
Standard of Care: Therapeutic Options for Anemia in CKD
Anemia in CKD: CHOIR and TREAT Trials
Anemia in CKD: CHOIR and TREAT Trials
Economic Burden of Anemia in CKD
Economic Burden of Anemia in CKD
Treatment of Anemia in CKD During COVID-19
Treatment of Anemia in CKD During COVID-19
HIF Stabilizers for Anemia in CKD: Phase 3 Trials
HIF Stabilizers for Anemia in CKD: Phase 3 Trials
HIMALAYAS Trial: Long-Term Cardiovascular Safety Data
HIMALAYAS Trial: Long-Term Cardiovascular Safety Data
HIF Stabilizers: Management of Anemia in CKD
HIF Stabilizers: Management of Anemia in CKD
Payer Perspective of HIF Stabilizers for Anemia in CKD
Payer Perspective of HIF Stabilizers for Anemia in CKD
Anemia in CKD: HIF Stabilizers in Clinical Trials
Anemia in CKD: HIF Stabilizers in Clinical Trials
Future Treatment of Anemia in CKD: Impact of HIF Stabilizers
Future Treatment of Anemia in CKD: Impact of HIF Stabilizers
Future Management of Anemia in CKD
Future Management of Anemia in CKD

Patient Management of Chronic Fibrosing Interstitial Lung Disease With Progressive Phenotype

What Is Interstitial Lung Disease?
What Is Interstitial Lung Disease?
Chronic Fibrosing ILD With Progressive Phenotype
Chronic Fibrosing ILD With Progressive Phenotype
Signs of Chronic Fibrosing ILD With Progressive Phenotype
Signs of Chronic Fibrosing ILD With Progressive Phenotype
Chronic Fibrosing ILD: Presentation and Comorbidities
Chronic Fibrosing ILD: Presentation and Comorbidities
How Is Chronic Fibrosing ILD With Progressive Phenotype Diagnosed?
How Is Chronic Fibrosing ILD With Progressive Phenotype Diagnosed?
Who Identifies and Manages Progressive Chronic Fibrosing ILD?
Who Identifies and Manages Progressive Chronic Fibrosing ILD?
Early Identification of Progressive Chronic Fibrosing ILD
Early Identification of Progressive Chronic Fibrosing ILD
Progressive Chronic Fibrosing ILD: Patient's Perspective
Progressive Chronic Fibrosing ILD: Patient's Perspective
Chronic Fibrosing ILD With Progressive Phenotype: Economic Burden
Chronic Fibrosing ILD With Progressive Phenotype: Economic Burden
Chronic Fibrosing ILD With Progressive Phenotype: Clinical Burden
Chronic Fibrosing ILD With Progressive Phenotype: Clinical Burden
Lack of Guidance in Progressive Chronic Fibrosing ILD
Lack of Guidance in Progressive Chronic Fibrosing ILD
Chronic Fibrosing ILD With Progressive Phenotype: Patient Education
Chronic Fibrosing ILD With Progressive Phenotype: Patient Education
Goals of Treating Chronic Fibrosing ILD With Progressive Phenotype
Goals of Treating Chronic Fibrosing ILD With Progressive Phenotype
Past Management of Chronic Fibrosing ILD
Past Management of Chronic Fibrosing ILD
Progressive Chronic Fibrosing ILD: Antifibrotic Agents
Progressive Chronic Fibrosing ILD: Antifibrotic Agents
Challenges of Chronic Fibrosing ILD With Progressive Phenotype
Challenges of Chronic Fibrosing ILD With Progressive Phenotype
Progressive Chronic Fibrosing ILD: Multidisciplinary Care
Progressive Chronic Fibrosing ILD: Multidisciplinary Care
Unmet Needs in Chronic Fibrosing ILD With Progressive Phenotype
Unmet Needs in Chronic Fibrosing ILD With Progressive Phenotype